CAR T-cell Therapy in Combination With Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma With High-Risk Prognostic Factors

NCT06567366 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

45

Enrollment

OTHER

Sponsor class

Conditions

Large B-cell Lymphoma

Interventions

BIOLOGICAL: CAR T-cell therapy
DRUG: Glofitamab
DRUG: Obinutuzumab

Sponsor

Ruijin Hospital